The UK's Competition and Markets Authority has issued a provisional opinion finding that Pfizer and Flynn Pharma charged "excessive and unfair" prices for anti-epileptic phenytoin sodium capsules, rocketing the cost for the NHS. But Pfizer claims that it tried to find a profitable and sustainable way of providing the loss-making drug to the NHS, complaining that the CMA is creating greater legal uncertainty for companies.
Pfizer said that an investigation into excessive pricing was "particularly troublesome in an industry that is already subject to price...






